Zobrazeno 1 - 10
of 45
pro vyhledávání: '"Masataka Katashima"'
Autor:
Ikumi Nakajo, Masanari Shiramoto, Hiroshi Inoue, Taiji Sawamoto, Hajimu Kurumatani, Keishi Oikawa, Masaki Inaba, Masataka Katashima
Publikováno v:
Clinical Drug Investigation. 41:549-555
Beraprost sodium (BPS), an orally administrable prostaglandin I2 derivative, is used for the treatment of chronic arterial occlusion and pulmonary arterial hypertension and has potential efficacy in nephropathy. Beraprost sustained release (beraprost
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::33f15776084fe00209d82df28c471366
https://doi.org/10.1007/s40261-021-01031-8
https://doi.org/10.1007/s40261-021-01031-8
Autor:
Masataka Katashima, Takayo Ueno, Nobuko Matsushima, Hirotaka Ando, Kumi Matsuno, Yasuhiko Imai
Publikováno v:
Rinsho yakuri/Japanese Journal of Clinical Pharmacology and Therapeutics. 51:151-160
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::451d493904f9440decdf89a2a5bdaa10
https://doi.org/10.3999/jscpt.51.151
https://doi.org/10.3999/jscpt.51.151
Autor:
Rui Ohashi, Takahiro Nakamura, Yoshiro Saito, Kosuke Saito, Seiji Tanaka, Masaaki Kakehi, Tamiki Mori, Hiroyuki Kakuo, Ryosuke Nakamura, Mizuki Horiuchi, Hiroyuki Yokoi, Harue Igarashi, Hiroyuki Shimizu, Masataka Katashima, Yoshiaki Ohtsu, Yutaka Yasuda, Takashige Okayama
Publikováno v:
Bioanalysis. 13(18)
Biomarkers are an important drug developmental tool. Assessment of quantitative analytical methods of biomarkers is not included in any regulatory documents in Japan. Use of biomarkers in clinical evaluations and supporting the post-marketing evaluat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::198984677fd35bab0bdf6925ce824de6
https://pubmed.ncbi.nlm.nih.gov/34517750
https://pubmed.ncbi.nlm.nih.gov/34517750
Autor:
Yuichiro Kaneko, Hisakuni Sekino, Masataka Katashima, Daisuke Miyatake, Tetsuya Nishimura, Akinori Urae, Kazuo Oda, Kenichi Furihata, Tomohisa Shibata, Mai Shibata
Publikováno v:
Clinical Drug Investigation
Background and Objective This study measured and compared the exposure and safety of peficitinib (ASP015K), a novel oral Janus kinase inhibitor, in subjects with normal and impaired renal function after a single oral, clinically relevant peficitinib
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9d979c9cfa82f550ee813b6b77b8545f
http://europepmc.org/articles/PMC6989572
http://europepmc.org/articles/PMC6989572
Autor:
Seiji Tanaka, Takahiro Nakamura, Yoshiro Saito, Yoshiaki Ohtsu, Masaaki Kakehi, Ryosuke Nakamura, Masanari Mabuchi, Takayoshi Suzuki, Hiroyuki Kakuo, Masataka Katashima, Noriko Katori, Takehisa Matsumaru
Publikováno v:
Bioanalysis. 11:55-60
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::32a8992c402dd4dd036c895751a9247a
https://doi.org/10.4155/bio-2018-0257
https://doi.org/10.4155/bio-2018-0257
Publikováno v:
Clinical therapeutics. 42(6)
Purpose The objectives of this study were to explore covariates of plasma quetiapine concentrations after oral administration of quetiapine extended-release formulation (XR), and to examine the exposure–response relationship in Japanese patients wi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::877ff39e8441021e608701c576cd259e
https://pubmed.ncbi.nlm.nih.gov/32518042
https://pubmed.ncbi.nlm.nih.gov/32518042
Autor:
Dorien Groenendaal-van de Meent, Akitsugu Takada, Yoshiaki Ohtsu, Kota Kato, Martin den Adel, Masataka Katashima
Publikováno v:
Clinical Pharmacology in Drug Development
Amenamevir is an inhibitor of the helicase‐primase enzyme complex developed for the treatment of varicella zoster virus. This mass balance study investigated the absorption, metabolism, and excretion of a single dose (200 mg) of 14C‐labeled amena
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::04dee74b89ad790645cfc9fe9b7d02a4
https://doi.org/10.1002/cpdd.630
https://doi.org/10.1002/cpdd.630
Publikováno v:
Journal of Clinical Pharmacy and Therapeutics. 43:633-639
What is known and objective Roxadustat is a hypoxia-inducible factor prolyl hydroxylase inhibitor currently being investigated for the treatment of anemia in chronic kidney disease. Lanthanum carbonate is a phosphate binder that is commonly used to t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7e304c148b76eaa30885dd1a3bdaaaf9
https://doi.org/10.1111/jcpt.12729
https://doi.org/10.1111/jcpt.12729
Autor:
Tomohisa Shibata, Akitsugu Takada, Mai Ueno, Yuki Nomura, Masataka Katashima, Rie Yazawa, Kenichi Furihata
Publikováno v:
Clinical Pharmacology in Drug Development
Roxadustat is a hypoxia‐inducible factor prolyl hydroxylase inhibitor in late‐stage clinical development for the treatment of anemia in chronic kidney disease. Spherical carbon adsorbent (SCA) is used in patients with chronic kidney disease and h
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::16ea4f1bfd1c412924c6dd30b625536e
https://doi.org/10.1002/cpdd.597
https://doi.org/10.1002/cpdd.597
Autor:
Masataka Katashima, Akitsugu Takada, Kota Kato, Daisuke Miyatake, Yuta Taniuchi, Taiji Sawamoto, Naoyuki Nakada
Publikováno v:
Drug Metabolism and Pharmacokinetics. 33:118-124
ASP7991 is a calcimimetic that acts on the calcium-sensing receptor on parathyroid cell membranes and suppresses parathyroid hormone (PTH) secretion in the treatment of secondary hyperparathyroidism. The mass balance and metabolite profile of [14C]AS
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::caa86604e128c69a7909e815dad35ee7
https://doi.org/10.1016/j.dmpk.2018.03.001
https://doi.org/10.1016/j.dmpk.2018.03.001